Liu MM, Wang C, Zhang YH, Wang RJ, Lu XM, Li PL, Wang YX, Gong PD, Liu N, Zhang T, Tian TT. Potential of thrombospondin-1 in treatment of polycystic ovary syndrome rat model: a preliminary study.
Gynecol Endocrinol 2021;
37:1020-1026. [PMID:
34282706 DOI:
10.1080/09513590.2021.1950682]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 06/16/2021] [Accepted: 06/29/2021] [Indexed: 10/20/2022] Open
Abstract
OBJECTIVE
Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disease in reproductive women, and the endocrine levels are also affected by diseases. The aim of this study was to determine the effect of thrombospondin-1 (TSP-1) on PCOS rat model.
METHODS
We established the PCOS rat model, the serum hormones including TSP-1 expression were determined and morphological characteristics were investigated to evaluate the model. These above endocrine and morphological features were investigated again to evaluate the effect of TSP-1 treatment.
RESULTS
In the PCOS model group, the serum hormones change (higher luteinizing hormone, testosterone and estrogen) and decreased TSP-1 expression levels were found compared with the control group. Besides, the morphological characteristics of PCOS were also observed in the model group. After TSP-1 treatment, the higher TSP-1, ANGPT2, PDGFB and PDGFD expression levels, the lower LH and T levels, decreased vessel density as well as VEGFA and ANGPT1 expression levels were found compared with the control group, and the ovary morphological changes were also observed in the TSP-1 experimental group.
CONCLUSIONS
TSP-1 delivery system might be an alternative therapy for PCOS treatment.
Collapse